Related Experiment Video
Updated: Apr 19, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
CD98 is a promising prognostic biomarker in biliary tract cancer
Kyoichi Kaira1, Yutaka Sunose, Noboru Oriuchi
1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, and Oncology Center, gunma University Hospital, Showa-machi, Maebashi, Gunma, Japan. kkaira1970@yahoo.co.jp.
Insights
High CD98 expression is common in biliary tract cancer and linked to poor outcomes. This suggests CD98 is vital for tumor growth and patient survival, highlighting its role in cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- CD98 is implicated in tumor progression and survival.
- The specific role of CD98 in biliary tract cancer (BTC) is not well-defined.
Purpose of the Study:
- To investigate the expression and prognostic significance of CD98 in biliary tract cancer.
- To explore the correlation between CD98 expression and clinicopathological features in BTC.
Main Methods:
- Immunohistochemical analysis of CD98 expression in BTC patient samples.
- Statistical correlation analysis (Spearman's rank correlation) with LAT1, Ki-67, and CD34.
- Multivariate analysis to assess prognostic value.
Main Results:
- High CD98 expression was observed in 36.7% of BTC patients.
- CD98 expression significantly correlated with L-type amino acid transporter 1 (LAT1), Ki-67, and CD34.
- High CD98 expression independently predicted poor patient outcomes.
Conclusions:
- CD98 expression is closely associated with tumor growth, aggressiveness, and survival in BTC.
- CD98 plays a necessary role in the development and pathogenesis of biliary tract cancer.
- CD98 represents a potential therapeutic target for biliary tract cancer.
Abstract:
CD98 has been described to play a crucial role in tumor progression and survival. However, the role of CD98 in biliary tract cancer remains unclear. We found that 36.7% of all patients with biliary tract cancer had a high CD98 expression. Statistical analysis using Spearman's rank correlation showed that CD98 was significantly correlated with L-type amino acid transporter 1 (LAT1, r=0.562, P<0.001), Ki-67 (r=0.230, P=0.006) and CD34 (r=0.290, P=0.005). Multivariate analysis confirmed that a high CD98 expression was an independent prognostic factor for predicting poor outcome. CD98 is closely associated with tumor growth, biological aggressiveness, and survival of patients. With these data we proposed that CD98 expression is necessary for the development and pathogenesis of biliary tract cancer.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023